Carcinoma esophagus

SAMMON A M (1998) Protease inhibitors and carcinoma of the esophagus. Cancer. 83 405-8. 

Esophagus (squamous carcinoma KYSE-30 cells) DOC Increase in p53 mutations 8... 

N. Katada, R. A. Hinder, T. C. Smyrk, N. Hirabayashi, G. Perdikis, R. J. Lund, T. Woodward and P. J. Klingler, Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus, Arch. Surg., 1997, 132(7), 728. 

Table 3 Paclitaxel in Preoperative Therapy for Carcinoma of the Esophagus ...

Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol 2001 24(1) 91—95. 

Type III tumor Subcardial gastric carcinoma, which infiltrates the esophagogastric junction and distal esophagus from below. 

Table 6 shows the results of five randomized studies of chemoradiation vs radiation alone. It is important to note that these studies consisted primarily of squamous cell carcinoma of the midesophagus. No studies have adequately evaluated this approach in adenocarcinoma of the esophagus. Thus, nonsurgical treatment approaches for adenocarcinoma are extrapolated from data based on trials of squamous cell carcinoma. 

Launois B, Delarue D, Campion JP, Kerbaol M. Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet 1981 153(5) 690-692. 

FokM, Sham JS, Choy D, Cheng SW, Wong J. Postoperative radiotherapy for carcinoma of the esophagus a prospective, randomized controlled study. Surgery 1993 113(2) 138-147. 

Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus a prospective randomized trial. J Thorac Cardiovasc Surg 1997 114(2) 210-217. 

Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988 96(2) 242-248. 

Ando N, Iizuka T, Kakegawa T, et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997 114(2) 205-209. 

Forastiere AA, Orringer MB, Perez-Tamayo C, Urba SG, Zahurak M. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus final report. J Clin Oncol 1993 11(6) 1118—1123. 

Smith TJ, Ryan LM, Douglass HO Jr, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998 42(2) 269-276. 

Minsky BD, Neuberg D, Kelsen DP, et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12) Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999 43(3) 517—523. 

Gaspar LE, Winter K, Kocha WI, Coia LR, Herskovic A, Graham M. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207) final report. Cancer 2000 88(5) 988-995. 

Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994 86(14) 1086-1091. 

Ratnasinghe D, Tangrea J, Roth MJ, et al. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus an immunohistochemical survey. Anticancer Res 1999 19 171-174. 

K. Kim, S.J. Park, B.T. Kim, K.S. Lee, Y.M. Shim, Evaluation of lymph node metastases In squamous cell carcinoma of the esophagus with positron emission tomography, Ann. Thorac. Surg. 71(1) (2001) 290-294. 

Rabdosia lasiocarpus (Flayata) Mao Guo Yan Ming Cao (whole plant) Terpenes, oridonin, rubescensins, 5-fluoro uracil.50 This herb is toxic. For carcinomas of esophagus and stomach, antiarthritic, antidotal, febrifuge. 

A 60-year-old man with type 2 diabetes received radiation therapy for a carcinoma of the esophagus and needed continuous enteric tube feeding (17). One daily injection of glargine controlled his diabetes well his HbAlc concentration was 6.1% and he had no episodes of hypoglycemia for almost 4 months. This made continuous infusion of a short-acting insulin unnecessary. 

Bleomycin (Blenoxane) causes chain scission and fragmentation of DNA. With the exception of the skin and lungs, most tissues can enzymatically inactivate bleomycin. Bleomycin is used in the management of squamous cell carcinoma of the head, neck, and esophagus in combination with other drugs in patients with testicular carcinoma, and in the treatment of Hodgkin s disease and other lymphomas. Bleomycin causes stomatitis, ulceration, hyperpigmentation, erythema, and pulmonary fibrosis. 

Table III lists results of carcinogenicity studies associated with zinc deficiency. These rats were given 17 doses of MBN, beginning at seven weeks of age. Fifty eight days after the first dose of MBN, all zinc-deficient rats had developed tumors of the esophagus, 83% of which were invasive carcinomas. Five weeks later, all deficient rats had tumors, 33% of which were invasive, clearly, a marked enhancement of carcinogenesis by zinc deficiency.

Cytotoxic—inhibits growth of carcinoma of the urinary bladder, breasts, esophagus, thorax, and lungs. Increases secretion of cytokins, mainly IL-1 and TNF-a factor Protective factor against cancer Stimulates development of breast cancer Being incorporated into cellular membranes, fats modulate the activity of macrophages. They disturb proliferation of lymphocytes and depress activity of cytotoxic cells They disturb the response dependent on both B and T cells... 

---